Christophe Boetsch
Basel, BS, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 26 publications
Simlukafusp alfa (FAP-IL2v) plus atezolizumab with or without bevacizumab in unresectable, metastatic renal cell carcinoma: a randomized, open-label phase Ib study.
Journal: Journal for immunotherapy of cancer
Published: February 02, 2026
FAP-Targeted LTβR Agonist Drives HEV Differentiation and Immune Niche Formation for Improved Immunotherapy Response in Solid Tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 23, 2025
Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of cergutuzumab amunaleukin: a phase I study in patients with advanced and/or metastatic solid tumors.
Journal: ESMO open
Published: November 05, 2025
Translational strategy to support the first-in-human study of a TCR-like T cell bispecific with an in vitro-based safety approach.
Journal: Frontiers in immunology
Published: October 31, 2025
Leveraging in vitro Tumor Cell Killing and Cytokine Release to Predict Cytokine Release Syndrome Associated with CD3 T-cell Bispecifics in Oncology: a Retrospective Analysis.
Journal: The AAPS journal
Published: July 22, 2025
Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen-Positive Advanced/Metastatic Solid Tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 01, 2025
Oncology Dose Optimization: Tailored Approaches to Different Molecular Classes.
Journal: Clinical pharmacology and therapeutics
Published: January 05, 2025
Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors.
Journal: Cancer research communications
Published: January 02, 2025
Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma.
Journal: Cancer research communications
Published: December 17, 2024
Mechanistic PKPD modeling to describe cytokine release associated with CD3 T-cell engager therapies.
Mechanistic PKPD modeling to describe cytokine release associated with CD3 T-cell engager therapies.
Journal: Frontiers in immunology
Published: July 12, 2024
Phase Ib Study of the Immunocytokine Simlukafusp Alfa (FAP-IL2v) in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 26, 2024
Industry Perspective on First-in-Human and Clinical Pharmacology Strategies to Support Clinical Development of T-Cell Engaging Bispecific Antibodies for Cancer Therapy.
Journal: Clinical pharmacology and therapeutics
Published: May 27, 2024
Last Updated: 09/26/2026